Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat

Journal of Gene Medicine

Volumn 12, Issue 4, 2010, Pages 385-398

  Fitzsimons, Helen L ^a,d   Riban, Veronique ^b   Bland, Ross J ^a,e   Wendelken, Jennifer L ^a   Sapan, Christine V ^a   During, Matthew J ^b,c  

^a Neurologix Inc   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d MASSEY UNIVERSITY   (New Zealand)

^e AGRESEARCH GRASSLANDS   (New Zealand)

Author keywords

Adeno associated virus; Biodistribution; Gene therapy; Glutamic acid decarboxylase; Parkinson's; Subthalamic nucleus

Indexed keywords

GLUTAMATE DECARBOXYLASE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BLOOD; BRAIN; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; GENE EXPRESSION; GENOME; HEALTH; HISTOLOGY; INJECTION; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; ORGAN; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; CRYOULTRAMICROTOMY; DEPENDOVIRUS; DNA PRIMERS; DNA, VIRAL; GENE THERAPY; GENETIC VECTORS; GLUTAMATE DECARBOXYLASE; IMMUNOHISTOCHEMISTRY; MOTOR ACTIVITY; PARKINSON DISEASE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBTHALAMUS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PRIMATES; RATTUS; RODENTIA;

EID: 77950913649     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1449     Document Type: Article

References (27)

1. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006; 60: 706-715. (Pubitemid 46048488)
2. Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007; 15: 62-68. (Pubitemid 46043650)
3. Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE- 120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007; 22: 1124-1132. (Pubitemid 47067222)
4. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-570. (Pubitemid 44296090)
5. Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 2006; 14: 571-577.
6. Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002; 298: 425-429. (Pubitemid 35176353)
7. Emborg ME, Carbon M, Holden JE, et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007; 27: 501-509. (Pubitemid 46310430)
8. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease. Lancet 2007; 369: 2097-2105. (Pubitemid 46935946)
9. Klein RL, Hamby ME, Gong Y, et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002; 176: 66-74. (Pubitemid 34762106)
10. Daadi M, Pivirotto P, Bringas P, et al. Distribution of AAV2- hAADC-transduced cells after three years in Parkinsonian monkeys. Neuroreport 2006; 17: 201-204. (Pubitemid 43100327)
11. Paxinos G, Watson C. The Rat Brain Atlas in Stereotaxic Coordinates. Elsevier Academic Press: Amsterdam, 1986.
12. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral ratmodels of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-787. (Pubitemid 30103682)
13. Edwards E, Kitt C, Oliver E, Finkelstein J, Wagster M, McDonald WM. Depression and Parkinson's disease: a new look at an old problem. Depress Anxiety 2002; 16: 39-48. (Pubitemid 34977122)
14. Voon V, Kubu C, Krack P, Houeto JL, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21(Suppl 14): S305-S327.
15. Porsolt RD, Lepichon M, and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments, Nature 1997; 266: 730-773.
16. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005; 29: 547-569. (Pubitemid 40755456)
17. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of the k-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003; 305: 323-330. (Pubitemid 36373867)
18. Cunningham J, Pivirotto P, Bringas J, et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 2008; 16: 1267-1275. (Pubitemid 351866058)
19. Ciron C, Cressant A, Roux F, et al. Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 2009; 20: 350-360.
20. Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage FH, Peterson DA. Targeted retrograde gene delivery for neuronal protection. Mol Ther 2002; 5: 50-56. (Pubitemid 34110480)
21. Paterna JC, Feldon J, Büeler H. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol 2004; 78: 6808-6817. (Pubitemid 38781518)
22. Feldblum S, Erlander MG, Tobin AJ. Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles. J Neurosci Res 1993; 34: 689-706. (Pubitemid 23150329)
23. Esclapez M, Tillakaratne NJ, Tobin AJ, Houser CR. Comparative localization of mRNAs encoding two forms of glutamic acid decarboxylase with nonradioactive in situ hybridization methods. J Comp Neurol 1993; 331: 339-362. (Pubitemid 23133529)
24. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR. Comparative localization of two forms of glutamic acid decarboxylase and theirmRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci 1994; 14: 1834-1855. (Pubitemid 24080030)
25. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease. A consecutive series of 24 patients; Neurology 2002; 59: 1427-1429. (Pubitemid 35286000)
26. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders. Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-707. (Pubitemid 34557009)
27. Temel Y, Boothman LJ, Blokland A, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. PNAS 2007; 104: 17087-17092. (Pubitemid 350210996)